Phase 3 Front-MIND Trial Initiated to Explore Tafasitamab Triplet in DLBCLJune 16th 2021
A phase 3 trial has been initiated to explore the potential of a triplet regimen of tafasitamab-cxix, lenalidomide, and R-CHOP as a treatment options for patients with newly diagnosed diffuse large B-cell lymphoma.
Rituximab Maintenance Improves Time-to-Next Treatment and OS in Patients With Mantle Cell LymphomaJune 14th 2021
Time-to-next treatment and overall survival were improved in a real-world study evaluating patients who received rituximab maintenance after first-line treatment with bendamustine and rituximab or R-CHOP in patients with mantle cell lymphoma, according to a retrospective analysis presented at the European Hematology Association 2021 Virtual conference.
Axi-Cel Outperforms Alternate Treatments in R/R Follicular LymphomaJune 14th 2021
Axicabtagene ciloleucel improved outcomes for patients with relapsed/refractory follicular lymphoma over currently available therapies, according to data from a comparative analysis of the ZUMA-5 and SCHOLAR-5 trials.
Naratuximab Emtansine With Rituximab Leads to Durable Responses in R/R DLBCLJune 12th 2021
Naratuximab emtansine in combination with rituximab showed deep responses and a duration of response that was not reached in patients with relapsed or refractory diffuse large B-cell lymphoma, according to findings from a phase 2 trial presented during the EHA 2021 Virtual Congress.
In R/R B-NHL, High Marks Achieved by C-CAR066June 8th 2021
A favorable safety profile and promising efficacy was seen with C-CAR066, a novel 2nd generation chimeric antigen receptor T-cell therapy targeting the CD20 antigen, in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed with prior CD19 CAR T-cell therapy.
FDA Accepts sNDA for Zanubrutinib for MZLMay 19th 2021
The FDA has accepted a supplemental new drug application for zanubrutinib for the treatment of adult patients with marginal zone lymphoma who have received 1 prior anti-CD20-based therapy. The agent was also granted priority review, with a Prescription Drug User Fee Act target action date of September 19, 2021.
FDA Lifts Partial Clinical Hold on Study of Odronextamab in FL and DLBCLMay 17th 2021
Regeneron is resuming enrollment of patients with follicular lymphoma and diffuse large B-cell lymphoma in monotherapy trial of odronextamab after the FDA lifted the partial clinical hold placed on the agent in December 2020.
Single-Agent Loncastuximab Tesirine Shows Durable Efficacy and Safety in R/R DLBCL TreatmentMay 17th 2021
The LOTIS-2 phase 2 study of loncastuximab tesirine continued to show durable responses and tolerability in relapsed or refractory patients with DLBCL, according to the most recent published results.
Liso-Cel for Patients With R/R LBCL Shows Promising Results in Real-World SettingsMay 15th 2021
Patients with relapsed or refractory aggressive large B-cell lymphoma showed promising results from the administration of lisocabtagene maraleucel in both inpatient and outpatient non–university hospital settings.
Success of CAR T Cells in Blood Cancers Calls for Further Expansion into the Solid Tumor ArenaMay 7th 2021
In an interview with Targeted Oncology, Bishop, discussed how CAR T cells have reshaped the treatment landscape, the future of their use, and their potential in solid tumors.
Liso-Cel Efficacy Not Impacted by Prior CD19 Exposure in LBCLApril 25th 2021
In an interview with Targeted Oncology, Scott R. Solomon, MD, a medical oncologist with the Blood and Marrow Transplant Program, Leukemia and Cellular Immunotherapy Program at the Northside Hospital Cancer Institute, discussed the efficacy of liso-cel in large B-cell lymphoma patients with prior anti-CD19 exposure and future research.
Lenzilumab Plus Axi-Cel Achieves Responses in 100% of Patients With DLBCL With Limited Toxicity in Small StudyApril 23rd 2021
When given at the recommended phase 2 dose, lenzilumab in combination with taxicabtagene ciloleucel, induced a 100% objective response rate while showing no severe cytokine release syndrome cases or severe neurotoxicity in patients with relapsed or refractory diffuse large B-cell lymphoma.
Clinical Pearls in Management of Relapsed/Refractory Follicular LymphomaApril 22nd 2021
Citing clinical pearls from her own experience in working with patients with relapsed/refractory follicular lymphoma, Kami Maddocks, MD, gives advice to colleagues in their efforts to combat follicular lymphoma.
Treatment Challenges Beyond Second-Line in Relapsed/Refractory Follicular LymphomaApril 22nd 2021
The challenges faced in treating patients beyond second-line treatment are addressed. Kami Maddocks, MD, reviews the frequency of patients who require third- and fourth-line treatment, in addition to the factors that affect treatment decisions in later lines of therapy.